2017
DOI: 10.4172/2161-0460.1000353
|View full text |Cite
|
Sign up to set email alerts
|

Citicoline as Add-On Treatment in Alzheimer’s Disease: Tips from the Citicholinage Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
2
0
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 11 publications
0
2
0
1
Order By: Relevance
“…In the Citcholinage study [286] the association of citicoline with an acetylcholine esterase inhibitor was more effective that the acetylcholine esterase inhibitor alone in patients with Alzheimer's disease. These results encourage further investigation of the combined administration on demented patients and the effects on the progression of the disease [287].…”
Section: Experimental Datamentioning
confidence: 61%
“…In the Citcholinage study [286] the association of citicoline with an acetylcholine esterase inhibitor was more effective that the acetylcholine esterase inhibitor alone in patients with Alzheimer's disease. These results encourage further investigation of the combined administration on demented patients and the effects on the progression of the disease [287].…”
Section: Experimental Datamentioning
confidence: 61%
“…The association citicoline plus donepezil showed to be still better than citicoline plus rivastigmine. Definitely the present study showed that a cholinergic precursor such as citicoline plus an acetylcholinesterase inhibitor is able to slow down disease progression in Alzheimer’s disease patients [ 704 ]. Gareri et al [ 705 , 706 ] in the CITIMEM study showed the effectiveness of oral citicoline plus memantine in patients affected with Alzheimer’s disease and mixed dementia and encourage the role of this combined therapy in disease management and in slowing down the progression of disease.…”
Section: Clinical Experiencementioning
confidence: 97%
“…La asociación citicolina más donepecilo mostró ser aún mejor que citicolina más rivastigmina. Definitivamente, el presente estudio demostró que un precursor colinérgico como la citicolina más un inhibidor de la acetilcolinesterasa es capaz de ralentizar la progresión de la enfermedad en pacientes con enfermedad de Alzheimer [ 704 ]. Gareri et al [ 705 , 706 ], en el estudio CITIMEM, demostraron la eficacia de la citicolina oral más memantina en pacientes afectados de enfermedad de Alzheimer y demencia mixta, y fomentan el papel de esta terapia combinada en el manejo de la enfermedad y en la ralentización de su progresión.…”
Section: Experiencia Clínicaunclassified